

Innovation all for the patients



Roche A member of the Roche group

New Longer-Term Safety Data of Chugai's Satralizumab in Adults and Adolescents with Neuromyelitis Optica Spectrum Disorder Presented at EAN

TOKYO, May 22, 2020 -- [Chugai Pharmaceutical Co., Ltd.](#) (TOKYO: 4519) announced that Roche issued a press release regarding the new longer-term safety data of satralizumab (development code: SA237) for the treatment of adults and adolescents with neuromyelitis optica spectrum disorder presented at the 6th Annual Meeting of the European Academy of Neurology. Satralizumab is an anti-IL-6 receptor recycling antibody created by Chugai.

Please refer to the link below for details of the press release:

- New longer-term data reinforce safety of Roche's satralizumab in adults and adolescents with neuromyelitis optica spectrum disorder

<https://www.roche.com/media/releases/med-cor-2020-05-22.htm>

###